2seventy has been slimming down since the fall of 2023 until it was left with nothing else but the Abecma partnership with BMS. The Cambridge, Massachusetts-based biotech had divested its cell ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement. Bristol Myers Squibb is stepping in to buy its Abecma partner 2seventy bio ...

BMS and 2seventy bio first teamed up in 2021. Credit: Moyo Studio via Getty Images. Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at ...